Amoeba SA (ALMIB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amoeba SA (ALMIB) has a cash flow conversion efficiency ratio of 0.644x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.45 Million ≈ $-4.04 Million USD) by net assets (€-5.36 Million ≈ $-6.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Amoeba SA (ALMIB) market capitalisation for the company's overall valuation and market capitalisation.
Amoeba SA - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Amoeba SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Amoeba SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amoeba SA ranked by their cash flow conversion efficiency. See how well can Amoeba SA service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Steady Safe TBK PT
JK:SAFE
|
0.359x |
|
Cofix Group Ltd
TA:CFX
|
0.532x |
|
JD Sports Fashion PLC
LSE:JD
|
0.285x |
|
Indo Acidatama Tbk
JK:SRSN
|
0.060x |
|
Defense Metals Corp
V:DEFN
|
0.000x |
|
Optipharm.CO.LTD
KQ:153710
|
0.037x |
|
Mondi PLC
LSE:MNDI
|
0.049x |
|
Kairous Acquisition Corp Ltd
NASDAQ:KACL
|
-0.008x |
Annual Cash Flow Conversion Efficiency for Amoeba SA (2012–2025)
The table below shows the annual cash flow conversion efficiency of Amoeba SA from 2012 to 2025. View Amoeba SA stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-5.36 Million ≈ $-6.27 Million |
€-6.13 Million ≈ $-7.16 Million |
1.143x | +182.19% |
| 2024-12-31 | €-10.41 Million ≈ $-12.17 Million |
€-4.22 Million ≈ $-4.93 Million |
0.405x | -75.44% |
| 2023-12-31 | €-3.94 Million ≈ $-4.61 Million |
€-6.50 Million ≈ $-7.60 Million |
1.649x | +349.19% |
| 2022-12-31 | €8.16 Million ≈ $9.54 Million |
€-5.40 Million ≈ $-6.32 Million |
-0.662x | +97.77% |
| 2021-12-31 | €198.68K ≈ $232.28K |
€-5.90 Million ≈ $-6.90 Million |
-29.704x | -1727.93% |
| 2020-12-31 | €2.00 Million ≈ $2.34 Million |
€-3.25 Million ≈ $-3.80 Million |
-1.625x | -89.00% |
| 2019-12-31 | €4.23 Million ≈ $4.94 Million |
€-3.64 Million ≈ $-4.25 Million |
-0.860x | +12.73% |
| 2018-12-31 | €5.41K ≈ $6.33K |
€-5.33K ≈ $-6.23K |
-0.985x | -142.87% |
| 2017-12-31 | €12.52K ≈ $14.64K |
€-5.08K ≈ $-5.94K |
-0.406x | -32.43% |
| 2016-12-31 | €18.63K ≈ $21.78K |
€-5.71K ≈ $-6.67K |
-0.306x | +22.04% |
| 2015-12-31 | €10.60K ≈ $12.39K |
€-4.16K ≈ $-4.87K |
-0.393x | +7.81% |
| 2014-12-31 | €2.80 Million ≈ $3.27 Million |
€-1.19 Million ≈ $-1.39 Million |
-0.426x | -136.98% |
| 2013-12-31 | €433.99K ≈ $507.38K |
€500.21K ≈ $584.79K |
1.153x | +771.59% |
| 2012-12-31 | €947.20K ≈ $1.11 Million |
€-162.56K ≈ $-190.04K |
-0.172x | -- |
About Amoeba SA
Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopath… Read more